Foghorn Therapeutics Inc (FHTX) — Capital Reinvestment Ratio

Latest as of March 2022: 0.00x

Foghorn Therapeutics Inc (FHTX) has a Capital Reinvestment Ratio of 0.00x as of March 2022, meaning it reinvests 0% of its operating cash flow ($271.53 Million) in capital expenditures ($247.00K). Check Foghorn Therapeutics Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

$271.53 Million
USD

Capital Expenditures

$247.00K
USD

Data as of

Mar 2022
Most recent filing

Foghorn Therapeutics Inc Capital Reinvestment Ratio (2022–2022)

This chart tracks Foghorn Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see how efficiently does Foghorn Therapeutics Inc generate cash.

Annual Capital Reinvestment Ratio for Foghorn Therapeutics Inc (2022–2022)

Year-by-year Capital Reinvestment Ratio for Foghorn Therapeutics Inc from 2022 to 2022. See FHTX FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2022 0.01x $193.61 Million $1.21 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow